

Revised: 15 March 2021

#### META-ANALYSIS

# A biofeedback-guided programme or pelvic floor muscle electric stimulation can improve early recovery of urinary continence after radical prostatectomy: A meta-analysis and systematic review

Alessandro Sciarra<sup>1</sup> | Pietro Viscuso<sup>1</sup> | Alessandro Arditi<sup>1</sup> | Gianna Mariotti<sup>1</sup> | Ettore De Berardinis<sup>1</sup> | Giovanni Battista Di Pierro<sup>1</sup> | Vittorio Canale<sup>1</sup> | | Alessandro Gentilucci<sup>1</sup> | Gian Maria Busetto<sup>1</sup> | Martina Maggi<sup>1</sup> | Michael L. Eisenberg<sup>2</sup> | Fernandino Vilson<sup>1</sup> | Benjamin I. Chung<sup>2</sup> | Matteo Ferro<sup>3</sup> | Stefano Salciccia<sup>1</sup> | Francesco Del Giudice<sup>1,2</sup>

<sup>1</sup>Department of Maternal-Infant and Urologic Sciences, 'Sapienza' University of Rome, Policlinico Umberto I Hospital, Rome, Italy

<sup>2</sup>Department of Urology, School of Medicine, Stanford University, Stanford, CA, USA

<sup>3</sup>Department of Urology, European Institute of Oncology (IEO), Milan, Italy

#### Correspondence

Alessandro Sciarra, Department of Maternal-Infant and Urologic Sciences, 'Sapienza' University of Rome. Policlinico Umberto I Hospital, Viale del Policlinico 151, Rome, 00161, Italy. Email: alessandro.sciarra@uniroma1.it

#### **Funding information**

This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

#### Abstract

**Purpose:** Urinary incontinence (UI) after radical prostatectomy (RP) is an early side effect after catheter removal. This systematic review and meta-analysis were conducted to compare different forms of non-invasive treatments for post-RP UI and to analyse whether the addition of biofeedback (BF) and/or pelvic floor muscle electric stimulation (PFES) to PF muscle exercise (PFME) alone can improve results in terms of continence recovery rate.

**Materials and Methods:** A literature search was performed following the PRISMA guidelines. We performed a cumulative meta-analysis to explore the trend in the effect sizes across subgroups during a 12-months follow-up.

**Results:** Twenty-six articles were selected. At baseline after RP and catheter removal, mean pad weight varied extremely. At 1- and 3-months intervals, mean difference in pad weight recovery from baseline was significantly higher using guided programs (BF, PFES or both) than using PFME alone (3-months: PFME 111.09 g (95%CI 77.59-144.59), BF 213.81 g (95%CI -80.51-508-13), PFES 306.88 g (95%CI 158.11-455.66), BF + PFES 266.31 g (95%CI 22.69-302.93); P < .01), while at 6- and 12-months differences were similar (P > .04). At 1- and 3-months intervals, event rate (ER) of continence recovery was significantly higher using guided programs than using PFME alone (3-months: PFME 0.40 (95%CI 0.30-0.49), BF 0.49 (95%CI 0.31-0.67), PFES 0.57 (95%CI 0.46-0.69), BF + PFES 0.75 (95%CI 0.60-0.91); P < .01), while at 6- and 12-months ERs were similar.

**Conclusions:** Regarding non-invasive treatment of UI secondary to RP, the addition of guided programs using BF or/and PFES demonstrated to improve continence

All authors listed gave a substantive contribution to this study and to this original article.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. © 2021 The Authors. International Journal of Clinical Practice published by John Wiley & Sons Ltd.

recovery rate, particularly in the first 3-month interval, when compared with the use of PFME alone.

#### 1 | INTRODUCTION

Although advancements of surgical techniques in recent years consistently reduced morbidity after radical prostatectomy (RP) for prostate cancer (PC). RP remains one of the most relevant causes of iatrogenic incontinence in men. Reported rates of urinary incontinence (UI) after RP vary from 5% to more than 40%, depending on the definition of UI and on the methods of evaluation.<sup>1-3</sup> UI after RP is mainly an early side effect, starting at catheter removal and is more significant in the first 6 months, affecting patient healthrelated quality of life. The most common causes of UI after RP are urethral sphincter deficiency, as well as bladder dysfunction.<sup>1</sup> In clinical practice, non-invasive and non-surgical therapies are usually attempted first. For instance, pelvic floor muscle exercises (PFME) can be to improve function of the pelvic floor by accomplishing urethral stability after RP.<sup>1</sup> Several forms of PFME are currently available, can be self-administered, or guided by a physiotherapist. As stated by European Association of Urology (EAU) guidelines, post-RP PFME does not cure UI, but may speed the recovery of continence. For a correct contraction of PF muscles, a specific biofeedback (BF)guided program (under visual, tactile, or auditory stimuli) can be used.<sup>4</sup> An alternative non-invasive treatment is a functional pelvic floor electrical stimulation (PFES).<sup>1,2,5</sup> PFES artificially stimulates the pudendal nerve and its branches to cause direct and reflex responses of the urethral and periurethral striated muscles.<sup>5</sup> Methods of delivery of ES vary considerably, and ES can also be combined with other conservative therapies, eg, PFME and BF.

There are several randomised prospective clinical trials evaluating the role of these non-invasive methods in managing post-RP UI. However, as stated by Cochrane reviews <sup>6,7</sup> and EAU guidelines,<sup>1</sup> the data are still controversial, and the level of evidence remains uncertain. Therefore, we performed a systematic review and metaanalysis on the role of non-invasive treatments, such as PFME without and with BF and PFES in patients with post-RP UI.

#### 2 | MATERIALS AND METHODS

#### 2.1 | Objective

The primary *aim* of this systemic review and meta-analysis is to analyse and compare a PFME (without BF) program with other noninvasive treatments, such as specific PFME using a BF-guided program, PFES, or their combinations in patients with post-RP UI. We analysed the effect of these procedures in terms of UI improvement (pad weight) and continence recovery (pad-free status) at different post-operative intervals, therefore to determine also a possible time-related effect.

### 2.2 | Search strategy

A literature search using electronic databases, such as PubMed, Medline, Web of Science, Scopus and the Cochrane library was performed without time limits. The search process was performed on a combination of the items ("urinary incontinence" and "radical prostatectomy" and "pelvic floor muscle exercise" and/or "biofeedback" and/or "pelvic floor electrical stimulation") without language restrictions and following the Preferred Reporting Items for Systematic review and Meta-Analyses (PRISMA) guidelines. Original and review articles were included and critically considered. We have not included abstracts or reports from meetings.

#### 2.3 | Selection of the studies and inclusion criteria

Entry into the analysis was restricted to data collected from original studies on clinical prospective trials including patients submitted to RP with post-surgical UI. Two authors (AS, AA) independently screened titles and abstracts of all articles using predefined inclusion criteria. The full-text articles were independently examined by three authors (AS, MM, PV) to determine whether or not they met the inclusion criteria. Then two authors (FDG, PV) extracted data from the selected articles. Final inclusion was determined by discussion of all investigators' evaluation.

Studies selected for inclusion met the following criteria: (a) UI after RP; b) at least one post-operative non-invasive treatment among PFME, BF-guided program, PFES, or their combination; (c) prospective analysis with a follow-up from 1 to 12 months; (d) evaluation using at least one of the following methods: questionnaires on urinary symptoms and voiding diaries, pad testing, continence recovery rate (pad-free rate).

Articles were excluded if (a) multiple reports were published on the same population; (b) data provided were insufficient for the outcomes described in the aim section; (c) failed to meet inclusion criteria.

#### 2.4 | Statistical analysis

Risk of bias (RoB) for all included studies was evaluated using the Review Manager (RevMan) (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration) tool for the assessment of the methodological quality of trials (Figure S1). The two reviewing authors independently assessed the methodological quality based on sequence generation, allocation concealment, blinding of patients and personnel, blinding of outcome assessors, incomplete outcome data, selective outcome reporting, intention-to-treat analysis, and additional sources of bias. Furthermore, publication bias was tested both by visual assessment of the Deeks' funnel plot and calculation of P value using the Deeks' asymmetry test. The Egger's regression test was implemented to explore the relative importance of small-study effect.

According to predetermined endpoints, we compared the available treatment arms using Standardised Mean Difference (SMD) and Event Rate (ER) with 95% confidence interval (CI) for mean pad weight (grams, g) and percentage of pad-free patients, respectively, at 1-, 3-, 6- and 12-months following baseline evaluation. Sensitivity analyses was performed to assess the contribution of each study to the pooled subgroup estimate by excluding individual trials one at a time and recalculating the pooled estimates for the remaining studies. Evaluation for presence of heterogeneity was done using<sup>8</sup> the following: (a) Cochran's Q-test with P < .05 signifying heterogeneity; (b) Higgins  $I^2$  test with inconsistency index ( $I^2$ ) = 0%-40%, heterogeneity might not be important: 30%-60%, moderate heterogeneity: 50%-90%, substantial heterogeneity; and 75%-100%, considerable heterogeneity.

The pooled SMD and ER estimate for each group of treatment was calculated using a random effects model. Our results are graphically displayed as forest plots, with pooled SMDs and ERs indicating overall mean pad weight and pad-free rate for each study arm. A recovery regimen for post-RP UI based on the sub-group comparison of PFME versus any other non-invasive interventions, and the multiple comparison of each single non-invasive rehabilitative program (ie, PFME versus BF versus PFES) was implemented.

Meta-regression analyses were performed using available continuous variables retrieved among the studies to assess potential source of heterogeneity, including year of publication, mean age of participants, sample size and mean baseline pad weight. The point estimates of the SMDs and ERs were obtained and plotted with the area of the circles proportional to the inverse of the squared standard errors of the studies included.

Furthermore, with regard to mean pad weight difference outcome, we performed a cumulative meta-analysis to explore the trend in effect sizes across subgroups as a function of mean baseline pad weight within the studies included, and at each follow-up visit assessed. Calculations were accomplished using Stata version 16.1 (Stata Corporation) with all tests being two sided, and statistical significance set at <0.05.

#### RESULTS 3

#### 3.1 | Studies included in the meta-analysis

Database searches initially yielded 237 article references. Of these, 156 were subsequently removed because of either duplication or failure to meet the inclusion criteria. Full-text articles were then reevaluated and critically analysed for the remaining 81 references. Of these, 55 did not meet the inclusion criteria. The remaining 26 articles were considered for our critical review and meta-analysis (Figure S2, Table 1).

### CLINICAL PRACTICE-WILEY 3.2 | Quality of studies and sample size

THE INTERNATIONAL JOURNAL OF

Of the 26 articles selected for the review, 4,5,9-32 all studies were prospective mono or multicentre clinical trials, and 24 were randomised with at least two treatment arms.<sup>4,5,9-16,18-24,26-32</sup> In some randomised studies, one of the two treatment arms did not meet our inclusion criteria in terms of treatment procedure, and therefore that specific arm was not included in our analysis.

Sample size of post-RP UI ranged from 30 to 205 patients across the 26 studies. None of these studies accurately defined the patient population, in terms of either pre-operative characteristics (preoperative lower urinary tract symptoms, prostate volume, PC stage, related diseases or treatments), or surgical techniques, that may influence post-operative UI. Therefore, it was not possible to stratify our results on the basis of these pre-operative and intra-operative variables. Follow-up during treatment ranged from 3 to 12 months.

### 3.3 Assessment of continence improvement

At baseline and during follow-up, post-RP continence status was mainly assessed using urinary symptom questionnaires, voiding diary, pad test results and rate of pad-free patients. In particular, an extreme heterogeneity of questionnaires was used among the different studies, so that we were not able to perform a comparison of results according to this parameter. Moreover, parameters reported in terms of voiding diary varied heterogeneously in number of incontinence episodes, number or volume of voids and number of pads used. Homogeneously, 16 studies 4,5,9-11,14,15,17-20,22-24,30,32 reported results in terms of 24-hour pad test and pad weight (in grams). In 21 studies. <sup>4,10-23,25,26,28,30-32</sup> continence was objectively defined as no pad use (pad-free status) or <2 g at 24-hours pad test. Only two studies reported some results in terms of urodynamic test.

#### **Baseline characteristics of populations** 3.4

In the 26 studies, mean age of populations ranged from 50.0 to 69.4 years. Baseline parameters were considered at different intervals after catheter removal, ranging from 1 to 30 d. At baseline, after RP and catheter removal, mean pad weight varied extremely from 7.0  $\pm$  56.3 g to 738.5  $\pm$  380.6 g. In particular, baseline mean pad weight was <200, 200-400 g and >400 g in seven,  $^{4,9,10,18,24,30,32}$  five <sup>11,15,17,19,23</sup> and four <sup>5,14,20,22</sup> studies, respectively.

### 3.5 | PFME, BF and PFES regimens

None of the studies included evaluated non-invasive or non-surgical therapies prior before surgery. The different treatment arms included PFME (without BF) in 24,4,5,9-13,15,16,18-32 PFME guided with BF in eight,<sup>4,10-14,16,29</sup> PFES in seven, <sup>5,9,14,18-20,22</sup> and PFME guided with BF + PFES in three <sup>17,21,23</sup> studies. Treatments started at

study author	Year	Study design	Treatments analysed	Patients for treatment group, n	Outcomes measurements	Follow-up zz(months)	Time between catheter removal and treatment (days)	Time for treatment session (minutes)	Sessions per week, n	Treatment period (weeks)
Laurienzo et al <sup>9</sup>	2018	RCT	<ul> <li>PFME not assisted</li> <li>PFES</li> </ul>	- 41 - 42	IPSS, Pad test	3, 6	- 30 - 30	- NR - NR	- NR - 2	- 24 - 24
Mathewson-Chapman et al <sup>10</sup>	1997	RCT	- BF - PFME not assisted	- 27 - 24	Bladder diary, Pad test	1, 3	- 21 - NR	- NR - NR	- 3 - NR	- 12 - 12
Moore et al <sup>11</sup>	2008	RCT	- PFME not assisted - BF	- 77 - 89	IPSS, Pad test	3, 6, 12	- 28 - 28	- NR - 30	- NR - NR	- 54 - 24
Ribeiro et al <sup>12</sup>	2010	RCT	- BF - PFME not assisted	- 26 - 28	ICSI, ICST, Pad test	1, 3, 6, 12	- NR - NR	- 30 - NR	- 1 - NR	- 12 - 12
Tienforti et al <sup>13</sup>	2012	RCT	- BF - PFME not assisted	- 16 - 16	ICIQ-UI, IPSS-QoL, Pad test	1, 3, 6	- 15 - 15	- 20 - 15	- NR - NR	- NR - NR
Van Kampen et al <sup>14</sup>	2000	RCT	- BF - PFES	- 48 - 50	Pad test	1, 3, 6, 12	- NR - NR	- NR - NR	- NR - NR	- 54 - 54
Dubbelman et al <sup>15</sup>	2010	RCT	<ul> <li>PFME assisted</li> <li>PFME not assisted</li> </ul>	- 33 - 33	Pad test	6	- NR - NR	- NR - NR	- NR - NR	- 26 - 26
Floratos et al <sup>4</sup>	2002	RCT	- BF - PFME not assisted	- 28 - 14	Pad test	1, 3, 6	- 7 - 7	- 30 - 10	- 3	- 24 - 24
Franke et al <sup>16</sup>	2000	RCT	- BF - PFME not assisted	- 15 - 15	Pad test	1, 3, 6	- NR - NR	- 45 - NR	- NR - NR	- 24 - 24
Mariotti et al $^{17}$	2015	Prospective	BF + PFES	60	ICS-male, Pad test	1, 3, 6	14	35	2	6
Gomes et al <sup>18</sup>	2018	RCT	- PFME assisted - PFES	- 34 - 35	Pad test	ო	- NR - NR	- 45 - 20	- NR - NR	- 10 - 10
Moore et al <sup>5</sup>	1999	RCT	<ul> <li>PFME assisted</li> <li>PFES</li> </ul>	- 18 - 19	Pad test	3, 6	- NR - NR	- 30 - 30	- 2	- 12 - 12
Pedriali et al <sup>19</sup>	2016	RCT	<ul> <li>PFME assisted</li> <li>PFES</li> </ul>	- 26 - 28	Pad test	ო	- NR - NR	- 45 - 20	 	- 10 - 10
Yokoyama et al [20]	2004	RCT	<ul><li>PFES</li><li>PFME not assisted</li></ul>	- 12 - 12	Pad test	1, 3, 6	- NR - NR	- 15 - NR	- 7 - NR	+ - + -
Wille et al <sup>21</sup>	2003	RCT	- PFME assisted - PFES - PFES + BF	- 47 - 46 - 46	Pad test	3, 12	1	- 20-30 - 15 - 15	- 14 - NR - 14	- 12 - 12 - 12
Yamanishi et al <sup>22</sup>	2007	RCT	<ul><li>PFES</li><li>PFME not assisted</li></ul>	- 26 - 30	Pad test	1, 3, 6, 12	- NR - NR	- 30 - NR	- NR - NR	φ 
Mariotti et al <sup>23</sup>	2009	RCT	- BF + PFES - PFME not assisted	- 30 - 30	Pad test	1, 3, 6	- 7 - NR	- 35 - NR	- 2 - NR	- 6

 TABLE 1
 Main data from the 26 studies considered in the meta-analysis

study author	Year	Study design	Treatments analysed	Patients for treatment group, n	Outcomes measurements	Follow-up zz(months)	Time between catheter removal and treatment (days)	Time for treatment session (minutes)	Sessions per week, n	Treatment period (weeks)
Fantawy et al <sup>24</sup>	2019	RCT	<ul> <li>PFME not assisted<sup>a</sup></li> <li>PFMS not assisted + whole body vibrations</li> </ul>	- 31 - 30	ICIQ-UI, Pad test	1, 3	R	Ŋ	ო	12
oan et al <sup>25</sup>	2019	Prospective	<b>PFME</b> not assisted	43	UISRP	1, 3	7	NR	NR	12
Manassero et al <sup>26</sup>	2007	RCT	<ul> <li>PFME not assisted<sup>a</sup></li> <li>Life style advices</li> </ul>	- 54 - 54	Pad test	1, 3, 6, 12	NR	NR	NR	48
Vilssen et al <sup>27</sup>	2012	RCT	<ul> <li>PFME assisted<sup>a</sup></li> <li>PFME not assisted</li> </ul>	- 42 - 43	UCLA-PCI, Pad test	3, 6, 12	1	45	Ţ	48
Glazener et al <sup>28</sup>	2011	RCT	- PFME assisted <sup>a</sup> - Life style advises	- 205 - 206	ICIQ-UI SF, Pad test	3, 6, 9, 12	NR	NR	NR	NR
Simeit et al <sup>29</sup>	2010	RCT	- PFME assisted - BF	- 87 - 72	SGUIS	1, 3, 6	- 14 - 14	- NR - NR	- 5 - 5	NR
Dark et al <sup>30</sup>	2012	RCT	<ul> <li>PFME not assisted<sup>a</sup></li> <li>PFME not assisted<sup>b</sup></li> </ul>	- 33 - 33	Pad test	ო	21	60	7	12
Filocamo et al <sup>31</sup>	2005	RCT	<ul> <li>PFME not assisted<sup>a</sup></li> <li>control group</li> </ul>	- 150 - 150	ICS, Pad test	1, 3, 6, 12	1	NR	٢	24
Dvergård et al <sup>32</sup>	2008	RCT	<ul> <li>PFME assisted<sup>a</sup></li> <li>PFME not assisted</li> </ul>	- 42 - 43	Pad Test	1, 3, 6, 12	1	45	7	48
vbbreviations: BF. biofeed	lback: ICIC	)-UI SF. Interna	tional Consultation on Incon	tinence-Urinar	v Incontinence Short Form: I	CS. Internation	al Continence Society:	: ICSI. Interstit	ial Cvstitis Svm	otom Index:

IPSS, International Prostate Symptom Score; NR, not reported; PFES, pelvic floor electrical stimulation; PFME, pelvic floor muscle exercises; QoL, quality of life; RCT, randomised controlled trial; SGUIS, St George Urinary Incontinence Score.; UCLA-PCI, UCLA Prostate Cancer Index; UISRP, Urinary Incontinence Scale after Radical Prostatectomy. <sup>a</sup>Only the first arm was considered in the analysis

bdifferent types at comparison.

**TABLE 1** (Continued)

#### 6 of 12

## ILEY CLINICAL PRACTICE

different intervals after catheter removal, ranging from 1 to 30 d. Different methods were used for each treatment regimen among studies, with different lengths, times and characteristics. PFME (without BF) was self-administered in 16<sup>4,9-13,15,16,20,22-27,31</sup> and physiotherapist guided in nine <sup>5,18,19,21,27-30,32</sup> studies. Time PFME sessions varied from 5 to 60 minutes with intervals from all days per week to just once per week.

PFME guided with a BF program were always performed under the assistance of a physiotherapist and varied regarding apparatus used and exercises performed. Time of BF sessions varied from 15 to 45 minutes, with intervals ranging from five to just once per week.

All studies with PFES treatments were performed with the assistance of a physiotherapist. In different studies, PFES was developed using different apparatus and pulsed from 4 to 50 Hz square waves at a pulse duration from 300 to 1000  $\mu$ s and a maximum output current from 24 to 70 mA. Time of PFES session varied from 15 to 30 minutes, with intervals from ranging twice to just once per week.

The combination of BF + PFES treatment was obtained starting with BF for the first 15 minutes followed by ES for the next 20 minutes, twice a week.

#### 3.6 Outcome results in terms of pad weight

According to previously declared random effect model, we first compared results between PFME alone and guided programs using BF, PFES, or both within 16 eligible studies.<sup>4,5,9-11,14,15,17-20,22-24,30,32</sup>

At 1-month interval after RP,<sup>4,10,14,17,20,22-24,32</sup> pooled SMD for pad weight recovery from baseline was significantly different with 59.6 (95%CI 30.7-88.6) and 271.0 (95%CI 147.1-394.9) for PFME alone and all guided programs together (BF, PFES or both), respectively ( $l^2$  85.7% and 99.4%, respectively; Q - *P* < .01). Stratifying results according to the different guided treatment programs, 1-month SMD from baseline varied significantly with 136.9 (95%CI 110.2-384.1), 457.3 (95%CI 218-696.6) and 215 (95%CI 174.5-255.4) for BF, PFES and BF + PFES, respectively (Test of group differences *P* < .01) (Figure 1A).

Similarly, at 3-month interval after RP <sup>4,5,9,11,14,17-20,22-24,30,32</sup> pad weight mean difference from baseline was 111.1 (95%CI 77.6-144.6) and 275.7 (95%CI 167.4-384.0), respectively for PFME alone and all guided programs together (BF, PFES or both) (I<sup>2</sup> 97.5% and 99.8%, respectively; Q - *P* < .01). Stratifying results according to the different guided treatment programs, at 3-month SMD from baseline varied significantly with 213.8 (95%CI 80.5-508.3), 306.9 (95%CI 158.1-455.7) and 266.3 (95%CI 229.7-302.9), respectively for BF, PFES and BF + PFES (Test of group differences *P* < .01) (Figure 1B).

Differently,at6-and12-monthsoffollow-up,<sup>4,5,9,11,14,15,17,20,22,23,32</sup> SMDs from baseline were similar between PFME alone and guided programs using BF, PFES, or both (6-months: PFME 262.2, 95%CI 170.7-353.8 and guided programs 340.5, 95%CI 195.7-485.3, P = .37; 12-months: PFME 303.2, 95%CI 161-445.5 and guided programs 423.0, 95%CI 382.8-463.2, P = .11; Figure 1C,D).

Deeks' funnel plots, as well as results from the Egger's regression test for each single follow-up evaluation, are displayed in Figure S3.

Meta-regression plots and analysis are presented in Figure S4. Notably, we found a constantly positive association between the higher baseline mean pad weight and the subsequent improved SMD recovery over the follow-up. This moderator was therefore explored as the possible cause for the consistent heterogeneity retrieved among the studies and a subgroup analysis stratifying for the guartiles baseline pad weight distribution has been performed and shown in Figure S5. This resulted in a significant reduction in the heterogeneity findings per each single follow-up interval, corroborating the role of initial incontinence variability as a critical predictor among the included studies. For this reason, we explored in a cumulative meta-analysis the relative effect size variation as function of the increasing initial incontinence burden confirming that as the number of initial mean pad weight increased, the overall SMD and its significance (P-value) increased with a similar trend observed per each subgroup analysis and follow-up interval (Figure 2).

# 3.7 | Outcome results in terms of continence rate recovery

A meta-analysis was implemented in order to examine the rate of a complete continence recovery (pad-free rate or pad weight <2 g) with 95%CI obtained at the different follow-up intervals (1-,3-,6-,12-months) among the groups of treatment. Considering a random effect model among 21 eligible studies, <sup>4,10-23,25,26,28,30-32</sup> we first compared results between simple PFME without BF and guided programs using BF, PFES, or both.

At 1-month interval after RP,<sup>11-15,17,22,23,25,26,31</sup> ER of continence recovery was 0.16 (95%CI 0.10-0.22) and 0.41 (95%CI 0.27-0.55), respectively for PFME alone and all guided programs together (BF, PFES, or both) (I<sup>2</sup> 53.6% and 74.7%, respectively; Q - P < .01). Stratifying results by the different guided treatment programs, at 1-month ER of continence recovery varied significantly with 0.38 (95%CI 0.18-0.58), 0.24 (95%CI 0.11-0.36) and 0.66 (95%CI 0.48-0.83) for BF, PFES and BF + PFES, respectively (Test of group differences P = .03) (Figure 3A).

Similarly, at 3-month interval after RP, <sup>10-19,21-26,30-32</sup> ER of continence recovery was 0.40 (95%Cl 0.30-0.49) and 0.59 (95%Cl 0.47-0.71), for PFME alone and all guided programs together, respectively (I<sup>2</sup> 68.6% and 65.3%, respectively; Q - P = .00). Stratifying results by the different guided treatment programs at 3-months ER of continence recovery varied significantly with 0.54 (95%Cl 0.32-0.75), 0.57 (95%Cl 0.46-0.69) and 0.75 (95%Cl 0.60-0.91), for BF, PFES and BF + PFES, respectively (Test of group differences P = .00) (Figure 3B).

On the contrary, at 6- and 12-month intervals, ERs of continence recovery  $^{4,11-17,20-23,26,28,31,32}$  were similar between PFME alone and guided programs using BF, PFES, or both (6-months: PFME 0.59, 95%CI 0.42-0.76 and guided programs 0.80, 95%CI 0.66-0.94, Test of group differences P = .07; 12-months: PFME 0.76, 95%CI





Pad Weight at Bas 39.00 317.90 416.00

o-value 0.000 0.187 0.154 0.000 0.291 0.322 0.104

SMD #h 86% CI

long.

ad Weight at Baseline

-value SMD th 95% CI

B

ad Weight at Bas 39 76.8 416

outer-c 0.000 0.000 0.278 0.000 0.000

SMD th 95% CI

Study

Pad Weight at Baseline

P-value

SMD with 95% CI

€

Study Guidder Programs Cuidder Programs Martenson D., 2002 Martens 6, 2015 Wark Kiampien M. 2000 Van Kiampien M. 2000 Van Kiampien M. 2000 Vansanishi T. 2004 Vansanishi T. 2004

Stacky Guided Programs Laurienzo CE, 2018 Floratos DL, 2002 Gomes CS, 2018 Manotti G, 2005 Manotti G, 2005 Manotti G, 2015

Guided Programs				BF								Elvestra DI 2002		3501 355 4451 0000	10.00
Floratos DL, 2002	ŧ	21.0 [ 9.4, 32.6] 0.000	39	Floratos DL, 2002	•	21.0[ 9.4, 32.6] 0.000	38	Classics Dr. 2010	E +	ien kir ver len	00.00	Moore KN, 2008	[	110.2   -53.5, 274.0   0.187	317.90
Mathewson Chapman M, 1:	266	21.3 [ 9.7, 32.9] 0.000	176.8	Namewson-Unapman M. 1997 Van Kamnen M. 2000	• [	21.31 9.7, 32.31 0.000 136.91.510.2 384.11 0.228	416	Gornes CS. 2018	ŧ	29.91 1.4. 58.41 0.040	177.40	Van Kampen M. 2000 -		213.8[-80.5, 508.1] 0.154	416.00
Marlotti G, 2009	[	101.9 [-37.6, 241.4] 0.152	291	concert from transferment rank				Pedrial FR, 2016	ł	64.7 3.6, 125.8 0.038	188.28	BF & PFSE			
Mariotti G, 2015	[	132.2 [ -0.6, 265.0] 0.051	295	BF & PFES Manual C 2000	ł	0000 11535 0551 14845	100	Mariotti G, 2009	ł	91.4 33.1, 149.7 0.002	291.00	Mariceti G, 2009	ł	274.3 [ 162.2, 386.5] 0.000	291.00
Van Kampen M, 2000		· 173.6[ -5.9, 353.0] 0.058	416	Mariotti G. 2015	ŧ	215.01 174.5. 255.41 0.000	295	Mariotti G, 2015	Į	124.7 [ 64.9, 184.6] 0.000	295.00	Mariotti G, 2015	£	266.3 [ 229.7, 302.9] 0.000	295.00
Van Kampen M, 2000	[	191.3 [53.3, 329.4] 0.007	440	0000				Moore KN, 2008	ł	133.1 76.4, 189.9 0.000	317.90	PFES			
Yokoyama T, 2004		- 240.1 [109.4, 370.7] 0.000	684	Ven Kampen M. 2000		274.01 258.9 289.11 0.000	440	Van Kampen M. 2000		176.2 58.5, 283.9 0.003	416.00	Laurienzo CE, 2018	4	7.5[-8.4, 21.4] 0.201	900
Yamanishi T, 2007			738.5	Yokovama T. 2004		429.01 98.9.759.11 0.011	684	Van Kampen M. 2000		203.5 81.6, 325.3 0.001	440.00	Devicing ED 2016	f {	2220 010483, 14830 0.322	06.1/1
PFME				Yamanishi T, 2007	[	457.3[218.0, 696.6] 0.000	738.5	MODIE KN, TABB	[	211.4   94.8, 32/.9   0.000	452.50	Van Kampen M. 2000		163.81 -24.0, 351.61 0.067	440.00
Floratos DL. 2002	ŧ	20.01 7.9. 32.11 0.001	31					Yoroyama 1, 2004		244.5 [132.3, 355.8] 0.000	00.5460	Mcore KN, 1999	[	186.7   16.0, 357.4] 0.032	452.50
Tantany SA. 2018	e	26.41 18.6. 34.21 0.000	06	FINE FIGURE 11 2002		20.01 79 32.11 0.001	31	Yamanishi I, 2007		- 2/0./ [10/.4, 384.0] UUUU	/38.50	Yokoyama T, 2004	[	252.9 [ 94.2, 411.6] 0.002	684.00
Mathematica Phonese M 16		20 2 [ 24 0 24 6] 0 000	100 5	Tantawy SA 2018		26.41 18.6 34.21 0.000	5 9	PFME				Yamanishi T, 2007	[	306.9 [158.1, 455.7] 0.000	738.50
			1001	Mathewson-Chanman M. 1907		28.31 24.9 31.61 0.000	168.5	Launenzo CE, 2018	ŧ	5.0 [-12.8, 22.8] 0.582	7.00	PFME			
CONSTRUCTION CONST	E		5	Overdard M. 2008	4	40.2   18.6, 61.8 0.000	184	Floratos DL, 2002	f	18.5 [ -6.0, 42.9] 0.139	31.00	Laurienzo CE, 2018	ŧ	5.0 [-12.8, 22.8] 0.552	2.00
Mariotti Gi, 2009	ŧ	41.4[ 20.2, 62.6] 0.000	290	Mariotti G. 2009	•	41.41 20.2 62.61 0.000	290	Park SW, 2012	ŧ	24.2 [ 9.5, 38.9] 0.001	80.00	Floratos DL, 2002	ŧ	18.5 -6.0, 42.9 0.139	31.00
Yokoyama T, 2004	ŧ	53.2 [ 25.5, 80.9] 0.000	664	Yokovama T. 2004	ŧ	53.21 25.5 80.91 0.000	664	Tantawy SA, 2018	•	28.8 [ 18.1, 39.5] 0.000	00'06	Park SW, 2012	•	24.2   9.5, 38.9] 0.001	80.00
Yamanishi T, 2007	ł	59.6[ 30.7, 88.6] 0.000	6.9.9	Yemenishi T, 2007	ŧ	59.6[ 30.7, 88.6] 0.000	679.9	Overgard M, 2008	f	55.2 23.7, 86.7 0.001	184.00	Tantawy SA, 2018		28.8 [ 18.1, 39.5] 0.000	00.06
	0 100 200 200	٩						Gornes CS, 2018	ł	59.0 [ 28.5, 89.4] 0.000	198.79	Overgard M, 2008	ŧ	55.2 23.7, 85.7 0.001	184.00
	200 200 200	2			8			Pedrisii FR, 2016	ł	70.7 [ 35.7, 105.7] 0.000	223.42	Gomes CS, 2018	ŧ	59.0 [28.5, 89.4] 0.000	198.79
								Moore KN, 2008	ł	78.8 44.9, 112.6 0.000	242.20	Pedrial FR, 2016	ŧ	70.7 35.7, 105.7 0.000	223.42
								Mariotti G, 2009	ł	82.4 [ 49.4, 115.5] 0.000	290.00	Moore KN, 2008	f	78.8 44.9, 112.6 0.000	242.20
								Moore KN, 1999	ł	90.0 57.3, 122.8 0.000	385.90	Mariotti G. 2009	ŧ	82.4 49.4, 115.5 0.000	290.00
								Yokoyama T, 2004	ł	100.9 [ 67.6, 134.3] 0.000	664.00	Woore KN, 1989	ŧ	90.01 5/3, 122.8] 0.000 100.01 67.6 124.21 0.000	385-340 664 00
								Yamanishi T, 2007	ł	111.1 [ 77.6, 144.6] 0.000	679.90	Yamanishi T. 2007	ŧŧ	111.11 77.6 144.61 0.000	00*00
									0 100 200 300	[ <sup>ş</sup>		-	o an an an	and former were from	
(C)		UNS				- CARD		(Q)		UNS				ca to	
Study		with 95% CI P-value Pad M	feicht at Baseline	Shich		with 95% Cl P-value Pad	Weight at baseline	Study		with 95% CI P-value Pa	d Weight at Baseline	Study		SMU with 85% Cl P-value Pad	Weight at Baseline
Culded Became			0	BF				Guided Programs				BF			
				Floratos DI 2002		36.01 26.7 45.31 0.000	8	Moore KN, 2008	[	271.4 [ 173.9, 368.9] 0.000	317.9	Moore KN, 2008	F	271.4 [ 173.9, 368.9 ] 0.000	317.9
Launenzo CE, 2018	•	7.51 -3.0, 18.0] 0.161	20	Moore KN 2006	[	50.01 -82.2 382.31 0.205	317.9	Van Kampen M, 2000		- 348.7   216.0, 481.4   0.000	416	Van Kampen M. 2000	[	348.7 [ 216.0, 481.4] 0.000	416
Floratos DL, 2002	f	21.9 [ -6.1, 49.8] 0.125	8	Van Kremnen M. 2000		20.7 [ -60.4 520.0] 0.116	910	Van Kampen M. 2000	ł	408.41.375.1.441.61 0.000	440	PFES			
Mariotti G, 2009	ŧ	48.3 [ 8.5, 88.1] 0.017	291	vali Natigati M, 2000	4	011'N [0'00CC '4'8C- ] /'8C	0	Vamanishi T 2007	-	423.01.382.8.463.21.0.000	2.00 K	Van Kampen M. 2000		437.0 [ 426.4, 447.6] 0.000	440
Mariotti G, 2015	-	38.6 [ 63.0, 214.3] 0.000	295	BF & PFES								Yamanishi T, 2007		568.8 [ 291.7, 846.0] 0.000	738.5
Moore KN, 2008	-	62.2[ 90.4, 234.0] 0.000	317.9	Mariotti G, 2009	£	37.5 [ 175.8, 399.3] 0.000	291	PFME				PFME			
Van Kampen M, 2000	[	15.9 40.6, 391.3 0.016	416	Mariotti G, 2015	4	38.0 [ 253.7, 322.3] 0.000	296	Overgard M, 2008	f	183.0 [ 163.4, 202.6] 0.000	184	Overgard M, 2008		183.0 [ 163.4, 202.6] 0.000	181
Non Kamnan M 2000		18 1 1 78 5 417 Z1 0 004	440	PFES				Moore KN, 2008	ł	195.6 [ 152.6, 238.6] 0.000	242.2	Moore KN, 2008	1	196.6[152.6, 238.6] 0.000	242.2
			101	Laurienzo C.F. 2018		7.5 G - 3.0 18.0 D 161	a	Yamarishi T, 2007	[	303.2 [ 161.0, 445.5] 0.000	6.679	Yamanishi T, 2007	[	303.2 [ 161.0, 445.5] 0.000	678.9
MUUE NV, 1999			100	Van Kampen M. 2000		22.21-198.7. 643.21 0.301	440	- <sup>t</sup>	0 200 300 400	۱ß		14	00 400 600 800		
Yokoyama I, 2004		00.9 [149.1, 452.7] 0.000	684	Moora KN 1999		24.01 -83.1 61111 0.136	462.6								
Yamanishi T, 2007		40.5 [195.7, 485.3] 0.000	738.5	Volcommun T 2004			604								
PFME				Yamanishi T, 2007		32.0 [ 159.3, 704.7] 0.002	738.5								
Laurienzo CE, 2018	ŧ	5.5[-14.9, 25.9] 0.597	7												
Overgard M, 2008		93.8[-79.2, 266.7] 0.288	184	Laurienzo CF. 2018	•	551 -149 2591 0.597	7								
Dubbelman Y, 2010	[	31.4 4.2, 258.6 0.043	211	Overclard M. 2008	[	33.81 -79.2, 266.71 0.288	184								
Moore KN, 2008	[	48.8 [ 39.1, 258.5] 0.008	242.2	Dubbelman Y, 2010	ŧ	31.4 4.2, 258.6 0.043	211								
Mariotti G, 2009	[	68.2 [ 68.3, 268.1 ] 0.001	290	Moore KN, 2008	ŧ	48.8 [ 39.1, 258.5] 0.008	242.2								
Moore KN, 1999	[	88.5 [ 94.9, 282.1] 0.000	385.9	Mariotti G, 2009	ŧ	38.2 [ 68.3, 268.1] 0.001	290								
Yokovama T, 2004	6	29.2 [ 136.1, 322.2] 0.000	664	Moore KN, 1999	ŧ	38.5 [ 94.9, 282.1] 0.000	385.9								
Yamanishi T, 2007	¢i	62.2 [ 170.7, 353.8] 0.000	679.9	Yokoyama T, 2004	ł	29.2 [ 138.1, 322.2] 0.000	664								
1				Yamanishi T, 2007	-	52.2 [ 170.7, 353.8] 0.000	679.9								
	0 200 400 600			-2005	0 500 1000										
							į						:	•	
E 2 Cumula	ntive meta-an.	alvsis for Pad V	Veight re	covervat 1	-(A) 3-(B)	6-(C) and 12	-(D) mont	hs within a	ll puided n	rogrammes ve	PE PE	MF and i	according	to each sing	ale recovel
4					~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~				L		5		D		

programme implemented within the studies included for analysis stratified by Pad Weight at baseline. BF, biofeedback; Cl, confidence interval; PFES, pelvic floor electric stimulation; PFME, pelvic floor muscle exercise; SD, standard deviation > FIGURE



programme implemented within the studies included for analysis. BF, biofeedback; Cl, confidence interval; PFES, pelvic floor electric stimulation; PFME, pelvic floor muscle exercise; SD, standard deviation FIGURE 3 Forrest plot assessing Pad-free Rate at 1-(A), 3-(B), 6-(C) and 12-months (D) follow-up within all guided programmes versus PFME, and according to each single-recovery

9 of 12

### LEY-CLINICAL PRACTICE

0.67-0.85 and guided programs 0.80, 95%CI 0.68-0.92, Test of group differences P = .62) (Figure 3C,D).

Deeks' funnel plots, as well as results from the Trim and Fill method and Egger's regression test for each single follow-up evaluation, are displayed in Figure S5 and suggest absence of any consistent heterogeneity among the studies for the aim of interest, while highlighting the existence of significant small-study effect over the follow-up.

Meta-regression plots and analysis are presented in Figure S6. Notably, at 1-month follow-up visit, we found an inversely negative association between mean age of participants and the higher padfree rate (Figure S7). This trend was not further confirmed at subsequent follow-up visits, suggesting the relative influence of age on early continence recovery only within the weeks following RP.

#### 3.8 | Strengths and limitations

Strengths: (a) the present meta-analysis considered objectives and included results different from previous studies; (b) all studies included are prospective and most are randomised; (c) the two parameters considered (ie, 24-h pad weigh and ER of continence recovery) are objectively and homogeneously defined in the different studies.

Limitations: (a) a high level of heterogeneity in mean difference in pad weight is present among studies; (b) a high level of heterogeneity in the baseline post-RP pad weight among studies is present; (c) studies did not accurately define pre-operative and intra-operative characteristics of the population.

### 4 | DISCUSSION

To our knowledge, this is the first meta-analysis evaluating noninvasive treatments for post-RP UI and comparing results among post-operative PFME and other specific programs guided by BF or using PFES. EAU guidelines summarise that PFME does not cure UI in men post-RP, yet it appears to speed the recovery of continence following surgery.<sup>1</sup> A 2015 Cochrane review stated that the benefits of conservative treatment in men with post-RP UI remain uncertain, and PFME does not produce significant benefit.<sup>33</sup> Moreover, the EAU guidelines underlined that there is conflicting evidence on whether the addition of BF increases the effectiveness of PFME alone and that PFES may add benefit in the short-term.<sup>1</sup>

In the present meta-analysis, we analysed studies only including post-operative non-invasive programs for the treatment of post-RP UI, trying to define whether the use of guided programs using BF or PFES may improve results obtained with only PFME.

Our study found a significant heterogeneity of results in terms of mean difference in pad weight (I<sup>2</sup> >80%). As demonstrated within other uro-oncologic surgically resected disease series varying from kidney to bladder cancer,<sup>34,35</sup> postoperative functional and/or survival outcomes can be influenced by a wide variable list of socio-demographic, racial, diagnostic, biochemical, procedural,

and patients-related features together with pre-, intra and/or early postoperative surgical counfunders.<sup>36,37</sup> Similarly, in the RP setting for PC, several well-established patient disease-specific, psychological as well as pathological features may condition UI after RP.<sup>38,39</sup> Unfortunately, these variables were not addressed or not adequately classified by all the selected studies as data regarding pre-operative conditions, co-morbidities, prostate volume and surgical techniques used to reduce the incidence of post-RP UI are in-

gical techniques used to reduce the incidence of post-RP UI are incomplete. All these variables likely conditioned the heterogeneity of UI levels detected in terms of pad weight at baseline after catheter removal. Therefore, in our meta-analysis we stratified results based on post-operative baseline pad weight instead of pre-operative or intraoperative variables. At baseline after RP and catheter removal, mean pad weight ex-

The baseline after RP and canteler removal, mean pad weight extremely varied from 7.0  $\pm$  56.3 to 738.5  $\pm$  380.6 g. Baseline pad weight is a variable able to condition the heterogeneity of results in terms of mean difference of pad weight improvement at different follow-up intervals. We found a consistently positive association between higher baseline mean pad weight and subsequent improved SMD recovery over the follow-up. A subgroup analysis stratifying for the quartiles of baseline pad weight distribution resulted in a significant reduction in the heterogeneity findings for each single follow-up interval, corroborating the role of initial incontinence variability as a critical predictor among the studies included. This effect was similar in the different treatment groups with a similar trend observed per each subgroup analysis and follow-up interval. The same analysis performed for the outcome ER of continence recovery suggested the absence of any consistent heterogeneity among the studies for this item.

Variability of results could be also conditioned by different treatment programs in terms of interval from catheter removal, time length of each session and of the entire treatment. Treatments started at different intervals after catheter removal ranging from 1 to 30 d. In particular, PFME programmes (without BF) were selfadministered in 16 and guided by physiotherapists in nine studies. Time of PFME session varied from 5 to 60 minutes, with intervals from 7 days to just once per week. On the contrary, PFME guided with a BF programme and PFES treatments were more homogeneously performed under the assistance of a physiotherapist and less variability in time of session and week intervals was present.

Our meta-analysis suggests that a specific BF-guided program or the addition of PFES to PFME significantly (P < .01) improve shortterm (1- and 3-month intervals) results, either in terms of pad weight reduction or continent rate (pad-free) recovery, when compared with the use of post-operative simple PFME assisted or without a physiotherapist. On the contrary, this advantage is not significant (P > .1) in long-term (6- and 12-months) follow-up, though results continue to be better adding BF and/or PFES to PFME. Notably, ER of continence recovery significantly increased up to 66% and 75%, at 1- and 3-month intervals, respectively when a PFES was added to PFME and BF, compared with an ER of 16% and 40% at 1- and 3-month interval, respectively when using PFME alone. At 6- and 12-month intervals, ER of continence recovery, although differences

CLINICAL PRACTICE WILEY-

were not statistically significant (P > .1), reached 96% and 91%, respectively adding a PFES and BF programme compared with 59% and 76%, respectively using PFME alone.

Some limitations associated to the present meta-analysis must be underlined. Populations considered from the different studies significantly varied in terms of baseline level of UI, as demonstrated by the post-surgical mean pad weight. As previously stated, patient characteristics significantly varied in terms of pre-operative and intra-operative variables were not accurately defined by the studies and, therefore, were not considered in our meta-analysis. However, the quality of the studies included in our analysis was high considering that all studies were prospective and most were randomised trials. The two parameters considered, pad weight and ER of continence recovery, are objectively and homogeneously defined in the different studies. We excluded parameters such as questionnaires or number of pads used as a result of the extremely heterogeneous data among the studies.

### 5 | CONCLUSIONS

The use of non-invasive therapies such as guided incontinence programmes (BF or/and PFES) in the management UI following RP for PC demonstrate improved incontinence recovery rate within the first 3 months following RP compared with PFME alone. While we would readily advise the need for a more comprehensive and standardised reporting approach in terms of clinical and perioperative variables (such as ICS Standards for incontinence or Dindo's Classification for the complications) in the studies analysing UI post-RP, future research should also better consider and stratify results according to pre-operative conditions and post-operative pad weight differences able to influence results among the different non-invasive treatment strategies.

#### DISCLOSURES

The Authors declare that they have no conflict to disclose.

#### AUTHORS' CONTRIBUTIONS

All authors contributed to the study conception and design. Alessandro Sciarra, Alessandro Arditi, Pietro Viscuso did conceptualisation. Ettore De Berardinis, Francesco Del Giudice, Alessandro Gentilucci performed methodology; Gian Maria Busetto, Benjamin I. Chung, Vittorio Canale, Gianna Mariotti did formal analysis and investigation; Alessandro Sciarra, Martina Maggi, Fernandino Vilson did writing - original draft preparation:; Stefano Salciccia, Michael L. Eisenberg, Giovanni Battista Di Pierro did writing - review and editing; Francesco Del Giudice and Matteo Ferro performed statistical analysis. All authors read and approved the final manuscript.

#### ORCID

Alessandro Sciarra (D https://orcid.org/0000-0002-7899-8056 Vittorio Canale (D https://orcid.org/0000-0001-5454-7982

#### REFERENCES

- EAU Guidelines. Edn. presented at the EAU Annual Congress. Amsterdam, 2020. ISBN 978-94-92671-07-3 https://uroweb.org/ guideline/urinary-incontinence/. Accessed on June 1, 2020.
- 2. Eastham JA, Kattan MW, Rogers E, et al. Risk factors for urinary incontinence after radical prostatectomy. *J Urol*. 1996;156:1707-1713.
- Hunter KF, Moore KN, Cody DJ, Glazener CM. Conservative management for postprostatectomy urinary incontinence. *Cochrane Database Syst Rev.* 2007;2:CD001843.
- Floratos DL, Sonke GS, Rapidou CA, et al. Biofeedback vs verbal feedback as learning tools for pelvic muscle exercises in the early management of urinary incontinence after radical prostatectomy. *BJU Int.* 2002;89:714-719.
- Moore KN, Griffiths D, Hughton A. Urinary incontinence after radical prostatectomy: a randomized controlled trial comparing pelvic muscle exercises with or without electrical stimulation. *BJU Int.* 1999;83:57-65.
- Campbell SE, Glazener CM, Hunter KF, Cody JD, Moore KN. Conservative management for postprostatectomy urinary incontinence. *Cochrane Database Syst Rev* 2012;1:CD001843.
- Berghmans B, Hendriks E, Bernards A, de Bie R, Omar MI. Electrical stimulation with non-implanted electrodes for urinary incontinence in men. *Cochrane Database Syst Rev.* 2013;6:CD001202.
- Higgins JPT, Altman DG. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions* (187–241). Chichester, England: John Wiley & Sons, 2008. www.handbook.cochrane.org. Accessed on November 11, 2018.
- Laurienzo CE, Magnabosco WJ, Jabur F, et al. Pelvic floor muscle training and electrical stimulation as rehabilitation after radical prostatectomy: a randomized controlled trial. J Phys Ther Sci. 2018;30:825-831.
- Mathewson-Chapman M. Pelvic muscle exercise/biofeedback for urinary incontinence after prostatectomy: an education program. J Cancer Educ. 1997;12:218-223.
- Moore KN, Valiquette L, Chetner MP, Byrniak S, Herbison GP. Return to continence after radical retropubic prostatectomy: a randomized trial of verbal and written instructions versus therapist-directed pelvic floor muscle therapy. Urology. 2008;72:1280-1286.
- Ribeiro LH, Prota C, Gomes CM, et al. Long-term effect of early postoperative pelvic floor biofeedback on continence in men undergoing radical prostatectomy: a prospective, randomized, controlled trial. J Urol. 2010;184:1034-1039.
- Tienforti D, Sacco E, Marangi F, et al. Efficacy of an assisted lowintensity programme of perioperative pelvic floor muscle training in improving the recovery of continence after radical prostatectomy: a randomized controlled trial. *BJU Int.* 2012;110:1004-1010.
- Van Kampen M, De Weerdt W, Van Poppel H, De Ridder D, Feys H, Baert L. Effect of pelvic-floor re-education on duration and degree of incontinence after radical prostatectomy: a randomised controlled trial. *Lancet*. 2000;355:98-102.
- Dubbelman Y, Groen J, Wildhagen M, Rikken B, Bosch R. The recovery of urinary continence after radical retropubic prostatectomy: a randomized trial comparing the effect of physiotherapist-guided pelvic floor muscle exercises with guidance by an instruction folder only. *BJU Int.* 2010;106:515-522.
- Franke JJ, Gilbert WB, Grier J, Koch MO, Shyr Y, Smith JA Jr. Early post-prostatectomy pelvic floor biofeedback. J Urol. 2000;163:191-193.
- Mariotti G, Salciccia S, Innocenzi M, et al. Recovery of urinary continence after radical prostatectomy using early vs late pelvic floor electrical stimulation and biofeedback-associated treatment. Urology. 2015;86:115-120.

## WILEY - CLINICAL PRACTICE

- Gomes CS, Pedriali FR, Urbano MR, Moreira EH, Averbeck MA, Almeida SHM. The effects of Pilates method on pelvic floor muscle strength in patients with post-prostatectomy urinary incontinence: a randomized clinical trial. *Neurourol Urodyn*. 2018;37:346-353.
- Pedriali FR, Gomes CS, Soares L, et al. Is pilates as effective as conventional pelvic floor muscle exercises in the conservative treatment of post-prostatectomy urinary incontinence? A randomised controlled trial. *Neurourol Urodyn.* 2016;35:615-621.
- Yokoyama T, Nishiguchi J, Watanabe T, et al. Comparative study of effects of extracorporeal magnetic innervation versus electrical stimulation for urinary incontinence after radical prostatectomy. Urology. 2004;63:264-267.
- 21. Wille S, Sobottka A, Heidenreich A, Hofmann R. Pelvic floor exercises, electrical stimulation and biofeedback after radical prostatectomy: results of a prospective randomized trial. *J Urol.* 2003;170:490-493.
- Yamanishi T, Mizuno T, Watanabe M, Honda M, Yoshida K. Randomized, placebo-controlled study of electrical stimulation with pelvic floor muscle training for severe urinary incontinence after radical prostatectomy. J Urol. 2010;184:2007-2012.
- Mariotti G, Sciarra A, Gentilucci A, et al. Early recovery of urinary continence after radical prostatectomy using early pelvic floor electrical stimulation and biofeedback associated treatment. *J Urol.* 2009;181:1788-1793.
- Tantawy SA, Elgohary HMI, Abdelbasset WK, Kamel DM. Effect of 4 weeks of whole-body vibration training in treating stress urinary incontinence after prostate cancer surgery: a randomised controlled trial. *Physiotherapy*. 2019;105:338-345.
- Pan LH, Lin MH, Pang ST, Wang J, Shih WM. Improvement of urinary incontinence, life impact, and depression and anxiety with modified pelvic floor muscle training after radical prostatectomy. *Am J Men Health*. 2019;13:1557988319851618.
- Manassero F, Traversi C, Ales V, et al. Contribution of early intensive prolonged pelvic floor exercises on urinary continence recovery after bladder neck-sparing radical prostatectomy: results of a prospective controlled randomized trial. *Neurourol Urodyn*. 2007;26:985-989.
- Nilssen SR, Mørkved S, Overgård M, Lydersen S, Angelsen A. Does physiotherapist-guided pelvic floor muscle training increase the quality of life in patients after radical prostatectomy? A randomized clinical study. *Scand J Urol Nephrol.* 2012;46:397-404.
- Glazener C, Boachie C, Buckley B, et al. Urinary incontinence in men after formal one-to-one pelvic-floor muscle training following radical prostatectomy or transurethral resection of the prostate (MAPS): two parallel randomised controlled trials. *Lancet*. 2011;378:328–337.Erratum in: Lancet. 2012; 379:412.
- Simeit R, Deck R, Drechsler T, Fiedrich M, Schönrock-Nabulsi P. Die Lebensqualität und die Bedeutung der Inkontinenz bei Männern mit Prostatakarzinom nach radikaler retropubischer Prostatektomie [Quality of life and impact of incontinence in male patients with prostate carcinoma after radical retropubic prostatectomy]. *Rehabilitation*. 2010;49:180-189.

- Park SW, Kim TN, Nam JK, et al. Recovery of overall exercise ability, quality of life, and continence after 12-week combined exercise intervention in elderly patients who underwent radical prostatectomy: a randomized controlled study. Urology. 2012;80:299-305.
- Filocamo MT, Li Marzi V, Del Popolo G, et al. Effectiveness of early pelvic floor rehabilitation treatment for post-prostatectomy incontinence. *Eur Urol.* 2005;48:734-738.
- Overgård M, Angelsen A, Lydersen S, Mørkved S. Physiotherapistguided pelvic floor muscle training reduce urinary incontinence after radical prostatectomy?. *Eur Urol.* 2008;54:438-448.
- Campbell SE, Glazener CM, Hunter KF, Cody JD, Moore KN. Conservative management for postprostatectomy urinary incontinence. *Cochrane Database Syst Rev.* 2012;1:CD001843.
- Cheung H, Wang Y, Chang SL, et al. Adoption of robot-assisted partial nephrectomies: a population-based analysis of U.S. surgeons from 2004 to 2013. *J Endourol.* 2017;31(9):886-892.
- Chung BI, Leow JJ, Gelpi-Hammerschmidt F, et al. Racial disparities in postoperative complications after radical nephrectomy: a population-based analysis. Urology. 2015;85(6):1411-1416.
- Nicolazzo C, Busetto GM, Del Giudice F, et al. The long-term prognostic value of survivin expressing circulating tumor cells in patients with high-risk non-muscle invasive bladder cancer (NMIBC). J Cancer Res Clin Oncol. 2017;143(10):1971-1976.
- Maggi M, Gentilucci A, Salciccia S, et al. Psychological impact of different primary treatments for prostate cancer: A critical analysis. *Andrologia*. 2019;51(1):e13157.
- Cotugno M, Martens D, Pirola G, et al. Adjustable bulbourethral male sling: Experience after 30 cases of moderate to severe male stress urinary incontinence. *Arch Ital Urol Androl.* 2020;92(1):7-10.
- Sciarra A, Voria G, Monti S, et al. Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A. *Prostate*. 2004;58:421-428.

#### SUPPORTING INFORMATION

Additional Supporting Information may be found online in the Supporting Information section.

How to cite this article: Sciarra A, Viscuso P, Arditi A, et al. A biofeedback-guided programme or pelvic floor muscle electric stimulation can improve early recovery of urinary continence after radical prostatectomy: A meta-analysis and systematic review. *Int J Clin Pract*. 2021;00:e14208. <u>https://</u>doi.org/10.1111/ijcp.14208